Compare · CDNA vs ELV
CDNA vs ELV
Side-by-side comparison of CareDx Inc. (CDNA) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDNA and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $86.50B, about 32.9x CDNA ($2.63B).
- Over the past year, CDNA is up 297.0% and ELV is up 28.7% - CDNA leads by 268.4 points.
- CDNA has hit the wire 11 times in the past 4 weeks while ELV has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 19 for CDNA).
- Company
- CareDx Inc.
- Elevance Health Inc.
- Price
- $50.82+6.98%
- $398.89-0.87%
- Market cap
- $2.63B
- $86.50B
- 1M return
- +39.77%
- +5.43%
- 1Y return
- +297.03%
- +28.66%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 11
- 0
- Recent ratings
- 19
- 23
CareDx Inc.
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CDNA
- Amendment: SEC Form SCHEDULE 13G/A filed by CareDx Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by CareDx Inc.
- SEC Form SCHEDULE 13G filed by CareDx Inc.
- Director Bickerstaff George sold $925,700 worth of shares (20,000 units at $46.28), decreasing direct ownership by 13% to 134,061 units (SEC Form 4)
- Director Cournoyer Christine sold $750,973 worth of shares (16,000 units at $46.94), decreasing direct ownership by 27% to 42,943 units (SEC Form 4)
- Secretary and General Counsel Novack Jeffrey Adam sold $124,349 worth of shares (2,688 units at $46.26) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,075 units (SEC Form 4)
- Director Goldberg Michael sold $2,103,497 worth of shares (44,700 units at $47.06), decreasing direct ownership by 42% to 61,738 units (SEC Form 4)
- Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,872 shares, decreasing direct ownership by 3% to 108,763 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by CareDx Inc.
- SEC Form 144 filed by CareDx Inc.
Latest ELV
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS